A detailed history of Massachusetts Financial Services CO transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 23,662 shares of ITOS stock, worth $171,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,662
Holding current value
$171,786
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.09 - $17.97 $238,749 - $425,206
23,662 New
23,662 $241,000
Q1 2024

May 14, 2024

SELL
$9.89 - $13.64 $1,661 - $2,291
-168 Reduced 0.22%
75,678 $1.03 Million
Q4 2023

Feb 08, 2024

SELL
$8.57 - $11.06 $20,542 - $26,510
-2,397 Reduced 3.06%
75,846 $830,000
Q3 2023

Nov 08, 2023

SELL
$10.95 - $14.6 $32,828 - $43,770
-2,998 Reduced 3.69%
78,243 $856,000
Q2 2023

Aug 09, 2023

SELL
$12.93 - $18.05 $24,735 - $34,529
-1,913 Reduced 2.3%
81,241 $1.08 Million
Q1 2023

May 10, 2023

SELL
$13.02 - $22.62 $530,018 - $920,814
-40,708 Reduced 32.87%
83,154 $1.13 Million
Q4 2022

Feb 13, 2023

BUY
$17.77 - $21.6 $46,592 - $56,635
2,622 Added 2.16%
123,862 $2.42 Million
Q3 2022

Nov 09, 2022

SELL
$18.6 - $27.25 $20,571 - $30,138
-1,106 Reduced 0.9%
121,240 $2.31 Million
Q2 2022

Aug 09, 2022

BUY
$16.57 - $35.1 $1.18 Million - $2.49 Million
70,959 Added 138.09%
122,346 $2.52 Million
Q1 2022

May 11, 2022

BUY
$31.92 - $47.45 $847,731 - $1.26 Million
26,558 Added 106.96%
51,387 $1.65 Million
Q4 2021

Feb 10, 2022

BUY
$26.23 - $47.86 $651,264 - $1.19 Million
24,829 New
24,829 $1.16 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.